CR20140575A - Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismo - Google Patents

Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismo

Info

Publication number
CR20140575A
CR20140575A CR20140575A CR20140575A CR20140575A CR 20140575 A CR20140575 A CR 20140575A CR 20140575 A CR20140575 A CR 20140575A CR 20140575 A CR20140575 A CR 20140575A CR 20140575 A CR20140575 A CR 20140575A
Authority
CR
Costa Rica
Prior art keywords
methods
tumor cells
insulation
purification process
assays
Prior art date
Application number
CR20140575A
Other languages
English (en)
Inventor
Cary Presant
Mathieu Perree
Allan Hallquist
Original Assignee
Diatech Oncology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatech Oncology filed Critical Diatech Oncology
Publication of CR20140575A publication Critical patent/CR20140575A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan en la presente métodos para aislar y purificar células tumorales hematológicas o no hematológicas útiles en una variedad de ensayos y procedimientos, incluyendo la detección de la eficacia del fármaco para tumores, tales como ensayos cinéticos de microcultivos. También se divulgan ensayos cinéticos de microcultivos y métodos adecuados para comparar la eficacia relativa de fármacos anticancerosos genéricos versus fármacos anticancerosos de marca.
CR20140575A 2012-05-15 2014-12-12 Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismo CR20140575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647248P 2012-05-15 2012-05-15
PCT/US2013/031300 WO2013172955A1 (en) 2012-05-15 2013-03-14 Tumor cell isolation/purification process and methods for use thereof

Publications (1)

Publication Number Publication Date
CR20140575A true CR20140575A (es) 2015-05-07

Family

ID=49584132

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140575A CR20140575A (es) 2012-05-15 2014-12-12 Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismo

Country Status (17)

Country Link
US (2) US20150160193A1 (es)
EP (1) EP2850434A4 (es)
JP (1) JP2015517662A (es)
KR (1) KR20150035537A (es)
CN (1) CN104704368A (es)
AU (1) AU2013263337A1 (es)
BR (1) BR112014028396A2 (es)
CA (1) CA2873180A1 (es)
CO (1) CO7240391A2 (es)
CR (1) CR20140575A (es)
HK (1) HK1208727A1 (es)
IL (1) IL235709A0 (es)
IN (1) IN2014DN09582A (es)
MX (1) MX2014013939A (es)
SG (1) SG11201407497TA (es)
TW (1) TW201409029A (es)
WO (1) WO2013172955A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
CA2900304C (en) * 2013-02-06 2024-06-04 Geissler Companies, Llc System and method for determining antibiotic effectiveness in respiratory diseased animals using auscultation analysis
EP3083692B1 (en) 2013-12-17 2020-02-19 F.Hoffmann-La Roche Ag Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
KR20180018538A (ko) 2015-06-17 2018-02-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
KR20220101204A (ko) 2016-03-02 2022-07-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
TWI662130B (zh) * 2018-09-21 2019-06-11 國立臺灣大學 分離循環癌細胞之方法
CN111019898B (zh) * 2019-02-14 2023-07-21 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系hjp-0320及其应用
CN111019899B (zh) * 2019-02-14 2023-08-04 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系lj-0429及其应用
CN111019897B (zh) * 2019-02-14 2023-08-11 中山大学孙逸仙纪念医院 人良性叶状肿瘤细胞系glk-1010及其应用
CN113466417B (zh) * 2021-05-13 2023-03-21 柳州东风容泰化工股份有限公司 一种氟尿嘧啶的制备纯度评估方法及系统
WO2024054627A1 (en) * 2022-09-08 2024-03-14 The University Of North Carolina At Chapel Hill Diagnosis of patient tumor tissue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251186A1 (en) * 1996-04-05 1997-10-16 The Johns Hopkins University A method of enriching rare cells
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
WO2002040702A2 (en) * 2000-11-09 2002-05-23 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
KR100721927B1 (ko) * 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
IT1391619B1 (it) * 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
BR112012024619A2 (pt) * 2010-03-31 2016-05-31 Diatech Oncology Llc sistema e método para avaliação de candidato a medicamento anticancer
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Also Published As

Publication number Publication date
WO2013172955A1 (en) 2013-11-21
IN2014DN09582A (es) 2015-07-17
TW201409029A (zh) 2014-03-01
US20170336391A1 (en) 2017-11-23
WO2013172955A9 (en) 2014-02-27
HK1208727A1 (en) 2016-03-11
MX2014013939A (es) 2015-05-11
CO7240391A2 (es) 2015-04-17
EP2850434A1 (en) 2015-03-25
SG11201407497TA (en) 2014-12-30
EP2850434A4 (en) 2016-01-13
KR20150035537A (ko) 2015-04-06
CA2873180A1 (en) 2013-11-21
CN104704368A (zh) 2015-06-10
AU2013263337A1 (en) 2014-12-04
JP2015517662A (ja) 2015-06-22
BR112014028396A2 (pt) 2018-05-29
US20150160193A1 (en) 2015-06-11
IL235709A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CR20140575A (es) Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismo
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
EP2922818A4 (en) HYDROPHILIC LINKS AND THEIR USES FOR CONJUGATION OF MEDICAMENTS TO CELL-BINDING MOLECULES
EA201590215A1 (ru) Макроциклические пурины для лечения вирусных инфекций
GB201106743D0 (en) Novel compounds
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
WO2013150495A3 (en) Preparation of ticagrelor
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
HK1204563A1 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
IN2015KN00073A (es)
EP2926806A4 (en) BIODEGRADABLE MICROBALL COMPRISING ANIONIC POLYMER FOR IMPROVING THE ADSORPTION CAPACITY OF ANTICANCER DRUGS, AND PREPARATION METHOD THEREOF
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12014502834A1 (en) Pharmaceutical form for extended release of active substances
WO2013188750A3 (en) Substituted macrocyclic compounds having proteasome inhibitory activity
MX358132B (es) Solucion de trombina y metodos de uso de esta.
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
MX2014010714A (es) Terapia de combinacion de procaspasa para gliobastoma.
MX2014015766A (es) Receptores de tipo toll y oligonucleotidos inmunoestimuladores.
WO2013190509A3 (en) Preparation of intermediates of boceprevir
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора